



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



PF-06649751

Item No. 33556

CAS Registry No.: 1643489-24-0
Formal Name: 1,5-dimethyl-6-[2-methyl-4-[[3-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-2,4(1H,3H)-pyrimidinedione

Synonym: CVL-751

MF: C₁₉H₁₆F₃N₃O₃

FW: 391.3


Purity: ≥98%

UV/Vis.: λ_{max}: 273 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-06649751 is supplied as a crystalline solid. A stock solution may be made by dissolving the PF-06649751 in the solvent of choice, which should be purged with an inert gas. PF-06649751 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PF-06649751 in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

PF-06649751 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PF-06649751 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PF-06649751 has a solubility of approximately 0.05 mg/ml in a 1:20 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PF-06649751 is a dopamine D₁ and D₅ receptor partial agonist.¹ It increases locomotor activity and reduces a global parkinsonian disability score in a macaque model of Parkinson's disease induced by MPTP when administered at a dose of 0.04 mg/kg.

Reference

1. Young, D., Popielek, M., Trapa, P., *et al.* D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects. *ACS Chem. Neurosci.* **11**(4), 560-566 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/26/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM